Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    PCSK9 inhibitors and dyslipidemia: The clinical evidence

    Access Status
    Fulltext not available
    Authors
    Norata, Giuseppe
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Norata, G. 2014. PCSK9 inhibitors and dyslipidemia: The clinical evidence. Giornale Italiano di Cardiologia. 15 (5): pp. 301-305.
    Source Title
    Giornale Italiano di Cardiologia
    DOI
    10.1714/1563.17029
    ISSN
    1827-6806
    School
    School of Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/55905
    Collection
    • Curtin Research Publications
    Abstract

    Elevated plasma LDL cholesterol (LDL-C) levels are associated with cardiovascular diseases and statin therapy was proven to decrease LDL-C and reduce cardiovascular death. However, in patients at high cardiovascular risk, achievement of optimal LDL-C levels is challenging, and therefore additional strategies for further lowering LDL-C levels are under development. Recently, silencing of apolipoprotein B gene and MTP inhibition have been approved for the treatment of patients with familial hypercholesterolemia, and there is great interest in the inhibition of proprotein convertase subtilisin/kexin 9 (PCSK9). PCSK9 promotes the degradation of the LDL receptor. The inhibition of PCSK9 favors LDL catabolism and reduces plasma LDL-C levels. Monoclonal antibodies against PCSK9 represent so far the most advanced approach in clinical development, with alirocumab, evolocumab and bococizumab under advanced clinical development. Recent data from the first phase III studies show LDL-C reduction in monotherapy and on top of statins. Long-term studies on cardiovascular endpoints are ongoing and the results will be crucial to translate the benefit of this promising approach into clinical practice. © 2014 Il Pensiero Scientifico Editore.

    Related items

    Showing items related by title, author, creator and subject.

    • Targeting PCSK9 for hypercholesterolemia
      Norata, Giuseppe; Tibolla, G.; Catapano, A. (2014)
      Dyslipidemias are a predominant risk factor for cardiovascular disease. Biological and genetic research has led to the identification of several genes and proteins that may be pharmacologically targeted to improve lipoprotein ...
    • PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
      Norata, Giuseppe; Tibolla, G.; Catapano, A. (2014)
      Hypercholesterolemia, is a prominent risk factor for cardiovascular disease (CVD). Undestanding of the biochemical mechanisms that regulate the expression of the low density lipoproteins receptor (LDLR) and the hepatic ...
    • Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
      Tibolla, G.; Norata, Giuseppe; Artali, R.; Meneghetti, F.; Catapano, A. (2011)
      Aims: This short review aims at summarizing the current information on Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) structure and function focusing also on the therapeutic possibilities based on the inhibition ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.